ClinicalTrials.gg
CompletedNCT03495817Updated Dec 9, 2020Results posted

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

A Phase 2 interventional study of ATI-50002 in Androgenetic Alopecia, sponsored by Aclaris Therapeutics, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2020-12-09.

Sponsored by Aclaris Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 217 studies in Alopecia with a site in United States — 44 open to participants now, 64 under way, 6 of them phase 3. Alopecia · United States.

Enrollment
126th of 204
31 · median 40
Started
2018
with 12 others
Phase 2
48 of 217
7 open now
Registered
86th of 217
by date

Among the 217 studies in Alopecia with a site in United States, this one is the 126th largest by enrollment of the 204 interventional ones that give a count, is one of 13 that started in 2018, is one of 48 in phase 2, and was the 86th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 128 are open to participants now.

Browse Alopecia studies →

Open to participants now

44 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.

Read the detailed description

This is an open-label study designed to evaluate the safety and efficacy of ATI-50002 Topical Solution in male and female subjects with androgenetic alopecia.

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male subjects and non-pregnant, non-nursing female subjects 18-50 years of age with a clinical diagnosis of androgenetic alopecia.

Subjects willing to agree to have a small circle of hair clipped to approx. 1mm in length on their balding spot.

Subjects willing to agree to have a permanent dot tattoo applied to their scalp to mark the center of the identified target area.

Subjects must agree to maintain the same hair style and hair care regimen during the study.

Exclusion criteria

Exclusion Criteria:

Females who are nursing, pregnant, or planning to become pregnant for the duration of the study and up to 30 days after the last application of study medication.

Clinical diagnosis of alopecia areata or other non AGA forms of alopecia. Scalp hair loss on the treatment area, due to disease, injury or medical therapy.

Active skin disease of the scalp (such as psoriasis or seborrheic dermatitis) or a history of skin disease on the scalp that in the opinion of the investigator would interfere with the study assessments or efficacy or safety.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    ATI-50002 Topical Solution

    This is an open-label phase 2 study designed to evaluate the safety and efficacy of ATI- 50002 Topical Solution, 0.46% in male and female subjects with androgenetic alopecia. Subjects will be required to apply ATI-50002 study medication to their scalp twice a day for a total of 26 weeks.

    Drug: ATI-50002

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Target Area Hair Count (TAHC)

    Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.

    Time frame: Baseline to 26 Weeks

Secondary outcomes

  1. Mean Change From Baseline in Target Area Hair Count (TAHC)

    Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.

    Time frame: Baseline to 52 Weeks

  2. Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)

    Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.

    Time frame: Baseline to 26 Weeks

  3. Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)

    Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.

    Time frame: Baseline to 52 Weeks

  4. Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale

    Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.

    Time frame: Baseline to 26 Weeks

  5. Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale

    Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.

    Time frame: Baseline to 52 Weeks

  6. Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale

    Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.

    Time frame: Baseline to 26 Weeks

  7. Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale

    Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.

    Time frame: Baseline to 52 Weeks

  8. Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale

    Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects. Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.

    Time frame: Baseline to 26 Weeks

  9. Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale

    Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects. Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.

    Time frame: Baseline to 52 Weeks

  10. Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale

    Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women. Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over. Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part. Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp. Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.

    Time frame: Baseline to 26 Weeks

  11. Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale

    Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women. Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over. Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part. Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp. Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.

    Time frame: Baseline to 52 Weeks

07

Results

Posted Dec 9, 2020

Participant flow

26 Week Open Label
Participant flow — 26 Week Open Label
MilestoneATI-50002 Topical Solution
Started31
Completed23
Not completed8
Withdrew: Adverse event3
Withdrew: Withdrawal by subject4
Withdrew: Lost to follow-up1
26 Week Extension
Participant flow — 26 Week Extension
MilestoneATI-50002 Topical Solution
Started19
Completed17
Not completed2
Withdrew: Lost to follow-up2

Outcome measures

PrimaryMean Change From Baseline in Target Area Hair Count (TAHC)

Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.

Time frame:
Baseline to 26 Weeks
Reported as:
Mean · hairs/cm^2
Mean Change From Baseline in Target Area Hair Count (TAHC)
hairs/cm^2ATI-50002 Topical Solution
Mean Change From Baseline in Target Area Hair Count (TAHC)8.6 ± 12.87
SecondaryMean Change From Baseline in Target Area Hair Count (TAHC)

Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.

Time frame:
Baseline to 52 Weeks
Reported as:
Mean · hairs/cm^2
Mean Change From Baseline in Target Area Hair Count (TAHC)
hairs/cm^2ATI-50002 Topical Solution
Mean Change From Baseline in Target Area Hair Count (TAHC)1.6 ± 18.92
SecondaryMean Change From Baseline in Cumulative Target Area Hair Width (TAHW)

Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.

Time frame:
Baseline to 26 Weeks
Reported as:
Mean · microns
Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)
micronsATI-50002 Topical Solution
Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)403.69 ± 817.271
SecondaryMean Change From Baseline in Cumulative Target Area Hair Width (TAHW)

Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.

Time frame:
Baseline to 52 Weeks
Reported as:
Mean · microns
Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)
micronsATI-50002 Topical Solution
Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)35.28 ± 901.082
SecondaryInvestigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale

Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.

Time frame:
Baseline to 26 Weeks
Reported as:
Count of participants · Participants
Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale
ParticipantsATI-50002 Topical Solution
Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale16
SecondaryInvestigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale

Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.

Time frame:
Baseline to 52 Weeks
Reported as:
Count of participants · Participants
Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale
ParticipantsATI-50002 Topical Solution
Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale8
SecondarySubject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale

Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.

Time frame:
Baseline to 26 Weeks
Reported as:
Count of participants · Participants
Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale
ParticipantsATI-50002 Topical Solution
Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale18
SecondarySubject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale

Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.

Time frame:
Baseline to 52 Weeks
Reported as:
Count of participants · Participants
Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale
ParticipantsATI-50002 Topical Solution
Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale13
SecondaryChange From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale

Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects. Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.

Time frame:
Baseline to 26 Weeks
Reported as:
Count of participants · Participants
Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale
ParticipantsATI-50002 Topical Solution
Improvement from Type V to Type III Vertex2
Improvement from Type V to Type IV1
Improvement from Type IV to Type III Vertex1
Improvement from Type III to Type III Vertex2
No Improvement Measured9
SecondaryChange From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale

Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects. Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.

Time frame:
Baseline to 52 Weeks
Reported as:
Count of participants · Participants
Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale
ParticipantsATI-50002 Topical Solution
Improvement from Type V to Type III Vertex1
Improvement from Type III Vertex to Type II1
Improvement from Type V to Type IV1
Improvement from Type IV to Type III Vertex1
Improvement from Type III Vertex to Type III1
No Improvement9
SecondaryChange From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale

Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women. Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over. Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part. Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp. Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.

Time frame:
Baseline to 26 Weeks
Reported as:
Count of participants · Participants
Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale
ParticipantsATI-50002 Topical Solution
Improvement from Grade 4 to Grade 31
Improvement from Grade 2 to Grade 11
No Measured Improvement5
SecondaryChange From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale

Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women. Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over. Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part. Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp. Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.

Time frame:
Baseline to 52 Weeks
Reported as:
Count of participants · Participants
Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale
ParticipantsATI-50002 Topical Solution
Improvement from Grade 4 to Grade 31
Improvement from Grade 3 to Grade 21
No Improvement1

Adverse events

Collected over Open Label = 26 weeks; Extension period = 26 weeks; Reporting of non-serious AEs started with each subject's first study medication application and continued until 30 days following the last application of study medication. Events with onset dates more than 30 days after the last application of study medication were considered as "post-therapy.". Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ATI-50002 Topical Solution0/31 (0%)1/31 (3.2%)18/31 (58.1%)
Most frequent serious events
Most frequent serious events
EventATI-50002 Topical Solution
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/31
Most frequent other events
Showing 10 of 30
Most frequent other events
EventATI-50002 Topical Solution
VertigoEar and labyrinth disorders2/31
Upper respiratory tract infectionInfections and infestations2/31
Neck painMusculoskeletal and connective tissue disorders2/31
AlopeciaSkin and subcutaneous tissue disorders2/31
PhotopsiaEye disorders1/31
ConstipationGastrointestinal disorders1/31
Gastroesophageal reflux diseaseGastrointestinal disorders1/31
Chest painGeneral disorders1/31
FolliculitisInfections and infestations1/31
InfluenzaInfections and infestations1/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)ATI-50002 Topical Solution
Mean38.2 ± 6.49
Sex: Female, Male
Sex: Female, Male(Participants)ATI-50002 Topical Solution
Female10
Male21
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ATI-50002 Topical Solution
Hispanic or Latino3
Not Hispanic or Latino21
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ATI-50002 Topical Solution
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander2
Black or African American1
White25
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)ATI-50002 Topical Solution
United States31
Height
Height(centimeters)ATI-50002 Topical Solution
Mean173.7 ± 9.04
Weight
Weight(kilograms)ATI-50002 Topical Solution
Mean89.4 ± 20.74
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)ATI-50002 Topical Solution
I - Always Burns3
II - Burns Easily11
III - Burns Moderately10
IV - Burns Minimally4
V - Rarely Burns2
VI - Never Burns1

5 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • Aclaris Investigational Site
    Denver, Colorado 80210, United States
  • Aclaris Investigational Site
    Portland, Oregon 97210, United States
  • Aclaris Investigational Site
    Austin, Texas 78759, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Oct 2019, 18 months.

Results were first posted in Dec 2020, 1 year 1 month after primary completion.

Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 18 months is above that.

Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2018
First posted
Apr 12, 2018
StartActual
Mar 22, 2018
Primary completionActual
Oct 15, 2019
CompletionActual
Oct 30, 2019
Results first posted
Dec 9, 2020
Last update
Dec 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03495817
Responsible party
Sponsor
First posted
Apr 12, 2018
Start date
Mar 22, 2018
Primary completion
Oct 15, 2019
Completion
Oct 30, 2019
Results posted
Dec 9, 2020
Last update
Dec 9, 2020

Study contacts

Stuart Shanler, MD
study chair · Aclaris Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifidancitinib

Start the discussion